Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 63
Filter
1.
Case Reports Hepatol ; 2018: 4298649, 2018.
Article in English | MEDLINE | ID: mdl-29955402

ABSTRACT

Hereditary hemochromatosis (HH) is a genetic disease associated with progressive iron overload, eventually leading in some cases to damage of parenchymal organs, such as the liver, pancreas, and heart. Although the gene had been identified (HFE), HH pathogenesis remains to be fully elucidated. We report here, for the first time, a case of inadvertent transplantation of a liver from a donor with C282Y/H63D compound heterozygosity into a nonhemochromatotic 19-year-old Caucasian male recipient with primary sclerosing cholangitis. Progressive iron overload occurred over 1.5 years, as observed in liver biopsies and iron studies, after ruling out secondary causes of iron overload. This case strengthens the hypothesis that the liver, rather than the small intestine, plays a primary role in the maintenance of iron homeostasis.

2.
Cancer Radiother ; 19(6-7): 410-5, 2015 Oct.
Article in French | MEDLINE | ID: mdl-26337474

ABSTRACT

Hepatocellular carcinoma is the major complication of chronic liver diseases and particularly of cirrhosis whatever its etiology. Once encountered mainly in the endemic countries of hepatitis B and C, the incidence of hepatocellular carcinoma (6/100,000) is parallel to the global development of diabetes, overweight and alcohol consumption. Little progress has been made for this cancer, whose mortality is 100 % at 10 years. Liver transplantation is the only truly curative treatment (survival more than 50 % at 10 years) since it allows the eradication of hepatocellular carcinoma and its essential cause, cirrhotic liver. This is the only possible therapy when liver function is impaired. It has little impact since in the richest countries, less than 10 % of cases can be transplanted. Surgical resection and percutaneous destruction methods (uni- and multipolar radiofrequency, microwave, cryotherapy, electroporation) are the preferred treatments (survival less than 50 % at 5 years) but are only applicable for moderate tumour masses and in the absence of adjuvant therapy, are effective only in the medium term. Most patients received chemoembolization through hepatic artery, whose action is modest. Radiotherapy is widely used in Asia but almost non-existent in Western countries in this indication. Sorafenib is the only effective drug but its impact is modest. Therapies combining two modalities (embolization and radiotherapy; embolization and radiofrequency) seem promising and deserve wider testing. Screening and monitoring of cirrhosis is probably the major measure for potentially curative therapies.


Subject(s)
Carcinoma, Hepatocellular/diagnosis , Carcinoma, Hepatocellular/therapy , Liver Neoplasms/diagnosis , Liver Neoplasms/therapy , Decision Trees , Humans
3.
Transpl Infect Dis ; 16(5): 827-9, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24981194

ABSTRACT

Infections remain a major cause of morbidity and mortality after liver transplantation. One possible cause of infection is preservation fluid contamination. Donor-derived pathogens, such as Candida albicans, have occasionally produced life-threatening complications in organ recipients, already described in renal transplantation. In the present case, we report the loss of a liver graft secondary to vascular complications because of C. albicans found in the preservation fluid. Our case report raises the question of implementing procedures, similar to those in renal transplantation, including early antifungal treatment and repeated radiological monitoring for the prevention and detection of vascular complications.


Subject(s)
Candidiasis/complications , Liver Transplantation/adverse effects , Liver , Organ Preservation Solutions/adverse effects , Shock, Septic/microbiology , Vascular Diseases/microbiology , Candida albicans , Fatal Outcome , Graft Rejection/immunology , Humans , Male , Middle Aged , Peritonitis/microbiology
4.
Aliment Pharmacol Ther ; 33(2): 163-74, 2011 Jan.
Article in English | MEDLINE | ID: mdl-21083593

ABSTRACT

BACKGROUND: Hepatitis C virus (HCV) infection is the first cause of liver transplantation worldwide. Recurrence of infection is constant, and compromises patient and graft survival. AIM: To provide an updated review of the main treatments of recurrent HCV. METHODS: MEDLINE (1990 to August 2010) and national meeting abstract search. Search terms included hepatitis C, liver transplantation, treatment, sustained virological response. An emphasis was placed on randomised trials. RESULTS: Anti-viral therapy based on pegylated interferon and ribavirin must be considered before liver transplantation, but is poorly tolerated and has poor results in patients with cirrhosis and end-stage liver disease or hepatocellular carcinoma. Anti-viral therapy can be administrated systematically early after liver transplantation, or in patients with established recurrent chronic hepatitis. Combination of pegylated interferon alpha plus ribavirin results in a sustained virological response of up to 30% in patients with histological HCV recurrence. The results of a small trial of polyclonal anti-HCV to prevent recurrence were disappointing. CONCLUSIONS: Currently available anti-viral therapy is effective only in a minority of transplanted patients infected with HCV. Specifically targeted anti-viral therapies combining interferon alpha and ribavirin, or a combination of antiprotease and antipolymerase components, associated with a genetic prediction of anti-viral response and blocking HCV cell entry should improve the long-term prognosis of recurrent hepatitis C in the near future.


Subject(s)
Antiviral Agents/therapeutic use , Hepacivirus/drug effects , Interferons/therapeutic use , Liver Transplantation/adverse effects , Ribavirin/therapeutic use , Drug Therapy, Combination , Hepatitis C, Chronic/drug therapy , Humans , Randomized Controlled Trials as Topic , Treatment Outcome
7.
Gut ; 57(9): 1268-74, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18480169

ABSTRACT

OBJECTIVE: Unsafe injections and transfusions used during treatments are considered to be responsible for many cases of transmission of hepatitis C virus (HCV) in developing countries, but cannot account for a substantial proportion of present infections. The aim of the present work was to investigate familial clustering of HCV infection in a population living in a highly endemic area. DESIGN, SETTING AND PARTICIPANTS: A large seroepidemiological survey was conducted on 3994 subjects (age range, 2-88 years) from 475 familial clusters in an Egyptian rural area. Epidemiological methods appropriate for the analysis of correlated data were used to estimate risk factors and familial dependences for HCV infection. A phylogenetic analysis was conducted to investigate HCV strain similarities within and among families. MAIN OUTCOME MEASURES: HCV familial correlations adjusted for known risk factors, similarities between viral strains. RESULTS: Overall HCV seroprevalence was 12.3%, increasing with age. After adjustment for relevant risk factors, highly significant intrafamilial resemblances in HCV seroprevalence were obtained between father-offspring (odds ratio (OR) = 3.4 (95% confidence interval (CI), 1.8 to 6.2)), mother-offspring (OR = 3.8 (95% CI, 2.5 to 5.8)), and sibling-sibling (OR = 9.3 (95% CI, 4.9 to 17.6)), while a weaker dependence between spouses (OR = 2.2 (95% CI, 1.3 to 3.7)) was observed. Phylogenetic analysis showed greater HCV strain similarity between family members than between unrelated subjects, indicating that correlations can be explained, in part, by familial sources of virus transmission. In addition, refined dissection of correlations between first-degree relatives supported the role of host genes predisposing to HCV infection. CONCLUSIONS: Current HCV infection in endemic countries has a strong familial component explained, at least partly, by specific modes of intrafamilial viral transmission and by genetic predisposition to infection.


Subject(s)
Hepatitis C/genetics , Hepatitis C/transmission , Adolescent , Adult , Age Distribution , Aged , Aged, 80 and over , Child , Child, Preschool , Egypt/epidemiology , Female , Genetic Predisposition to Disease , Hepacivirus/classification , Hepatitis C/epidemiology , Hepatitis C/virology , Humans , Infectious Disease Transmission, Vertical , Male , Middle Aged , Phylogeny , Reverse Transcriptase Polymerase Chain Reaction/methods , Risk Factors , Seroepidemiologic Studies , Sex Distribution
8.
Gut ; 52(6): 893-7, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12740348

ABSTRACT

BACKGROUND AND AIM: Autoimmune hepatitis (AIH) has been reported to recur after orthotopic liver transplantation (OLT) in 10-35% of patients in small series with a short follow up. The aim of the present study was to examine the clinical and histological outcome more than 10 years after OLT for AIH. PATIENTS AND METHODS: Seventeen women with a mean age of 30 (12) years at the time of OLT, selected from among 44 patients transplanted for AIH, were followed for more than 10 years. The criteria for definite AIH, as established by the International Autoimmune Hepatitis Group, were met in every case. Liver biopsies were performed 1, 2, 5, and 10 years after OLT, and when indicated by abnormal liver function tests. Specimens were examined for evidence of recurrent AIH, namely interface hepatitis, lobular activity, portal lymphoplasmocytic infiltration, and fibrosis. Other signs of recurrence included hypertransaminasaemia, serum autoantibodies, and the response to steroid reintroduction or significant steroid dose increments. RESULTS: AIH recurred in 7 (41%) of 17 patients. In four patients histological abnormalities were detected by means of protocol biopsies 1-5 years before the onset of biochemical abnormalities. Two patients developed severe recurrences after 10 and 15 years, respectively, and required treatment with steroids and tacrolimus. In the other three patients histological recurrence was detected 0.6-3 years post-OLT, concomitantly with biochemical abnormalities. CONCLUSIONS: AIH recurred in 41% of patients followed for more than 10 years after OLT. As histological signs preceded biochemical abnormalities in four patients (23.5%), regular liver biopsy is warranted after OLT. Detection of isolated histological signs may call for closer follow up and/or a change in immunosuppressive therapy.


Subject(s)
Hepatitis, Autoimmune/surgery , Liver Transplantation , Adolescent , Adult , Autoantibodies/blood , Autoantigens/immunology , Biomarkers/blood , Biopsy , Child , Drug Administration Schedule , Female , Follow-Up Studies , Glucocorticoids/administration & dosage , HLA-DR Antigens/analysis , Hepatitis, Autoimmune/immunology , Hepatitis, Autoimmune/pathology , Histocompatibility Testing , Humans , Immunosuppressive Agents/administration & dosage , Middle Aged , Prognosis , Recurrence
9.
J Clin Microbiol ; 40(5): 1648-50, 2002 May.
Article in English | MEDLINE | ID: mdl-11980935

ABSTRACT

Disseminated toxoplasmosis is a life-threatening disease in liver transplant recipients that can result from an organ-transmitted infection. We report here a case of fatal disseminated toxoplasmosis after orthotopic liver transplantation from a seropositive donor (immunoglobulin G [IgG](+) and IgM(-)) in a patient who was nonimmune for toxoplasmosis prior to transplantation. Quantitative PCR analyses of various clinical specimens, including serum samples, appeared retrospectively to be a valuable diagnostic tool that might guide therapeutic attitudes.


Subject(s)
Liver Transplantation , Postoperative Complications/parasitology , Toxoplasma/isolation & purification , Toxoplasmosis/diagnosis , Adult , Animals , Base Sequence , DNA Primers , Female , Humans , Polymerase Chain Reaction/methods , Transplantation, Homologous
10.
Gut ; 50(1): 95-9, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11772974

ABSTRACT

BACKGROUND AND AIMS: Liver donors with serological evidence of resolved hepatitis B virus (HBV) infection (HBV surface antigen (HBsAg) negative, anti-HBV core (HBc) positive) can transmit HBV infection to recipients. In the context of organ shortage, we investigated the efficacy of hepatitis B immunoglobulin (HBIG) to prevent HBV infection, and assessed the infectious risk by polymerase chain reaction (PCR) testing for HBV DNA on serum and liver tissue of anti-HBc positive donors. PATIENTS: Between 1997 and 2000, 22 of 315 patients were transplanted with liver allografts from anti-HBc positive donors. Long term HBIG therapy was administered to 16 recipients. Four naive and two vaccinated patients received no prophylaxis. RESULTS: Hepatitis B developed in the four HBV naive recipients without prophylaxis and in none of the vaccinated subjects. Among the 16 recipients receiving HBIG, one patient with residual anti-HBs titres below 50 UI/ml became HBsAg positive. The remaining 15 remained HBsAg negative and HBV DNA negative by PCR testing throughout a 20 month (range 4-39) follow up period. HBV DNA was detected by PCR in 1/22 donor serum, and in 11/21 liver grafts with normal histology. A mean of 12 months post-transplantation (range 1-23) HBV DNA was no longer detectable in graft biopsies from patients remaining HBsAg negative. CONCLUSION: Anti-HBs antibodies may control HBV replication in liver grafts from anti-HBc positive donors, without additional antiviral drugs. These grafts are thus suitable either to effectively vaccinated recipients or to those who are given HBIG to prevent HBV recurrence.


Subject(s)
Hepatitis B Core Antigens/immunology , Hepatitis B Surface Antigens/immunology , Hepatitis B virus/growth & development , Liver Transplantation/methods , Virus Activation/physiology , Antiviral Agents/therapeutic use , DNA, Viral/analysis , Hepatitis B virus/immunology , Hepatitis B, Chronic/drug therapy , Hepatitis B, Chronic/immunology , Humans , Immunoenzyme Techniques , Immunoglobulins, Intravenous/therapeutic use , Lamivudine/therapeutic use , Liver Transplantation/immunology , Polymerase Chain Reaction , Treatment Outcome
11.
J Virol ; 75(23): 11292-7, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11689609

ABSTRACT

The influence of viral factors on the severity of hepatitis C virus (HCV)-related liver disease is controversial. We studied 68 liver transplant patients with recurrent hepatitis C, of whom 53 were infected by genotype 1 strains. Relationships between core sequences, serum HCV RNA levels, and fibrosis scores for each patient were analyzed in pairwise fashion 5 years after transplantation. We used Mantel's test, a matrix correlation method, to evaluate the correspondence between measured genetic distances and observed phenotypic differences. No clear relationship was found when all 68 patients were analyzed. In contrast, when the 53 patients infected by genotype 1 strains were analyzed, a strong positive relationship was found between genetic distance and differences in 5-year fibrosis scores (P = 0.001) and differences in virus load (P = 0.009). In other words, the smaller the genetic distance between two patients' viral core sequences, the smaller the difference between the two patients' fibrosis scores and viral replication levels. No relationship was found between genetic distance and differences in age, sex, or immunosuppression. In multivariate analysis, the degree of fibrosis was negatively related to the virus load (r = -0.68; P = 0.003). In the particular setting of liver transplantation, and among strains with closely related phylogenetic backgrounds (genotype 1), this study points to a correlation between the HCV genetic sequence and the variability of disease expression.


Subject(s)
Hepacivirus/genetics , Hepatitis C, Chronic/physiopathology , Hepatitis C, Chronic/surgery , Liver Transplantation , Multigene Family , Genotype , Hepacivirus/isolation & purification , Hepatitis C, Chronic/virology , Humans , Multivariate Analysis , Phenotype , Phylogeny , Recurrence , Viral Load
12.
Gastroenterol Clin Biol ; 25(8-9): 773-80, 2001.
Article in French | MEDLINE | ID: mdl-11598539

ABSTRACT

AIM: Liver-graft shortages justify the development of adult living-related liver transplantation. The preliminary experience with this technique at Paul-Brousse Hospital is reported. PATIENTS ET METHODES: From January to July 2000, 7 adult to adult living-related liver transplantations were performed. Donors were 5 females and 2 males aged 20 to 53 years old (median: 41). A right liver graft was harvested in all cases. Recipients were 5 males and 2 females aged from 17 to 58 years old (median: 50) transplanted for viral cirrhosis (4 cases including 2 with hepatocellular carcinoma), subfulminant hepatitis (1 case), hepatocellular carcinoma on a healthy liver (1 case), and epithelioid hemangioendothelioma (1 case). Follow-up ranged from 41 to 157 days (median: 117 days). RESULTS: One donor had a biliary fistula that healed spontaneously. One donor had asterixis for 24 hours. The 7 donors are alive at home without any late complications. One recipient was retransplanted for hepatic artery thrombosis and 2 recipients had a biliary fistula that healed spontaneously. The 7 recipients are alive at home with normal liver function. CONCLUSION: Our experience and other reports suggest that adult to adult living-related liver transplantation is feasible with rare mortality and low morbidity in donors. Results in recipients are comparable to those obtained with cadaveric grafts. For a given patient the possibility of living related donation might extend the indications for transplantation without penalizing patients waiting for a cadaveric graft.


Subject(s)
Liver Transplantation , Living Donors , Adolescent , Adult , Carcinoma, Hepatocellular/surgery , Female , Humans , Liver Cirrhosis/surgery , Liver Cirrhosis/virology , Liver Neoplasms/surgery , Male , Middle Aged , Postoperative Complications
13.
J Med Virol ; 65(3): 493-504, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11596084

ABSTRACT

Lamivudine, an antiviral agent, has a potential role in the treatment of recurrent or acquired de novo hepatitis B virus (HBV) infection after liver transplantation. During lamivudine therapy, residual HBV particles in serum, PBMC, and liver were quantified in 7 patients in whom hepatitis B occurred de novo (n = 4) or recurred (n = 3). HBV DNA and preS1 antigen were measured using a sensitive PCR technique and an in-house ELISA method, respectively. The genetic and antigenic properties of HBV variants that emerged during lamivudine treatment were also examined. One month after the outset of lamivudine treatment, all 7 patients remained positive for both HBV DNA and preS1 antigen in serum, reflecting residual HBV replication. At the end of therapy, four patients were considered to be lamivudine responders, including one who seroconverted to anti-HBs but remained HBV DNA positive in the liver (> 10(3) copies/microg of DNA). Among the three patients who did not respond to lamivudine, one had pol mutations (L450P and S550C) that had not been described previously, in addition to the common mutations within the YMDD locus and B domain. Defective core and preS viral proteins and atypical sedimentation profiles of HBV DNA-positive particles were observed in all three lamivudine-resistant patients. These findings confirm the persistence of HBV in liver transplant recipients despite strong inhibition of replication by lamivudine, and show abnormal viral transcription and/or morphogenesis in lamivudine-resistant patients.


Subject(s)
DNA, Viral/blood , Hepatitis B Surface Antigens/blood , Hepatitis B virus/physiology , Hepatitis B/drug therapy , Lamivudine/therapeutic use , Liver Transplantation/adverse effects , Protein Precursors/blood , Adult , Aged , Alanine Transaminase/blood , Antiviral Agents/therapeutic use , Enzyme-Linked Immunosorbent Assay , Female , Hepatitis B/virology , Hepatitis B e Antigens/blood , Humans , Male , Middle Aged , Polymerase Chain Reaction , Virion/physiology , Virus Replication
16.
Liver Transpl ; 7(6): 556-8, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11443588

ABSTRACT

A 34-year-old woman underwent orthotopic liver transplantation (OLT) for decompensated type 1 autoimmune hepatitis (AIH). She was administered standard triple-drug immunosuppressive therapy (cyclosporine, steroids, and azathioprine). Ten years after OLT, she developed a recurrence of AIH, with emergence of serological markers of autoimmunity (high anti--smooth muscle antibody [ASMA] titer, high serum gamma globulin level), abnormal liver function test results, and characteristic histological features on liver biopsy. Despite intensified steroid therapy, her clinical and liver function deteriorated. The onset of cutaneous alternariosis led to a steroid dose reduction and cyclosporine replacement by tacrolimus. Clear-cut amelioration was observed, with an improvement in liver function test results and reduction in ASMA titer. One year after the recurrence of AIH, the patient has normal liver function and physical findings. Tacrolimus therefore may be effective in patients with severe recurrent autoimmune liver disease. Further studies are needed to assess tacrolimus therapy in patients who fail to respond to standard immunosuppressive therapy.


Subject(s)
Hepatitis, Autoimmune/drug therapy , Immunosuppressive Agents/therapeutic use , Liver Transplantation/adverse effects , Tacrolimus/therapeutic use , Adult , Alanine Transaminase/blood , Autoantibodies/blood , Female , Hepatitis, Autoimmune/immunology , Hepatitis, Autoimmune/pathology , Hepatitis, Autoimmune/surgery , Humans , Liver Transplantation/immunology , Liver Transplantation/pathology , Recurrence , gamma-Globulins/metabolism
17.
Eur Cytokine Netw ; 12(1): 69-77, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11282549

ABSTRACT

Patients with chronic hepatitis C present an imbalance of Th1/Th2 cytokine production. Therefore, we investigated whether the exposure of the CD4+ T cell line H9 to HCV could induce activation of cells through synthesis of IL-10. Three infection protocols were performed to enhance HCV propagation. Viral particles were prepared by ultracentrifugation of serum from patients. From 3 to 81 days post-infection (p.i.), HCV-RNA was monitored both in supernatants and cells by nested RT-PCR, IL-10 protein in medium by ELISA, and IL-10 mRNA in cells by semi-quantitative RT-PCR. The expression of tetraspanins was analyzed by flow cytometry. The PKC signal pathway was studied using specific inhibitors. The H9 cells express CD81. HCV-RNA (+) was detected in cells until 21 days p.i, and in culture media over 39 days p.i. Up to day 81 p.i., HCV exposure induced a specific, 2-fold increase of IL-10 production by H9 cells. IL-10 production was inhibited by a PKC inhibitor (Calphostin C). This study shows that even if the infection of H9 T cells did not result in any viral progeny, HCV induced the activation of IL-10 secretion, which supports the role of IL-10 in HCV pathogenesis.


Subject(s)
CD4-Positive T-Lymphocytes/metabolism , Hepacivirus/physiology , Interleukin-10/biosynthesis , Base Sequence , CD4-Positive T-Lymphocytes/enzymology , DNA, Viral , Enzyme-Linked Immunosorbent Assay , Humans , Interleukin-10/genetics , Phenotype , Polymorphism, Single-Stranded Conformational , Protein Kinase C/metabolism , RNA, Messenger/genetics , RNA, Viral/genetics , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction , Tumor Cells, Cultured
18.
Ann Dermatol Venereol ; 128(2): 130-3, 2001 Feb.
Article in French | MEDLINE | ID: mdl-11275588

ABSTRACT

BACKGROUND: Scopulariopsis brevicaulis is a causal agent of onchomycosis. We report the unusual clinical manifestations caused by this opportunist fungus. CASE REPORT: A 61-year-old man consulted in February 1997 for a budding lesion located on the right medial malleolus. This patient had had a liver transplantation for primary biliary cirrhosis in 1990 and had been taking prednisone and cyclosporine since this time. Cyclosporine had been recently replaced by tacrolimus. The histology examination of a lesion specimen taken from the ankle evidenced a dermal mycosis due to opportunist filamentous fungus. Total excision was performed. The patient then developed nodular lesions of the left elbow during the summer of 1997. Mycology culture of a skin biopsy grew numerous colonies of Scopulariopsis brevicaulis. Excision of the elbow lesion was delayed due to hospitalization for suspected graft rejection and development of insulin-dependent diabetes. The elbow lesion was then resected followed by a skin graft. The mycology examination identified the same causal agent. DISCUSSION: This liver transplant recipient developed two unusual extra-ungual localizations (ankle and elbow) of a Scopulariopsis brevicaulis infection. Chronic immunosuppression favored development of the infection with a pseudo-epithéliomatous presentation. The histology and mycology examinations were necessary for positive diagnosis.


Subject(s)
Dermatomycoses/diagnosis , Dermatomycoses/microbiology , Immunocompromised Host , Mitosporic Fungi , Opportunistic Infections/diagnosis , Opportunistic Infections/microbiology , Biopsy , Cyclosporine/adverse effects , Dermatomycoses/chemically induced , Dermatomycoses/immunology , Dermatomycoses/surgery , Humans , Immunosuppressive Agents/adverse effects , Liver Transplantation/immunology , Male , Middle Aged , Opportunistic Infections/chemically induced , Opportunistic Infections/immunology , Opportunistic Infections/surgery , Prednisone/adverse effects , Tacrolimus/adverse effects
19.
Transplantation ; 70(9): 1390-6, 2000 Nov 15.
Article in English | MEDLINE | ID: mdl-11087158

ABSTRACT

BACKGROUND: Recurrent hepatitis C virus (HCV) infection after liver transplantation is characterized by a high level of intrahepatic HCV replication and more severe liver damage in case of genotype 1b infection. We investigated the involvement of apoptosis in recurrent HCV liver disease, and its possible links with histological findings, HCV genotype, liver HCV RNA level, and liver Fas mRNA level. METHODS: We studied 61 liver graft biopsy specimens from 25 patients transplanted for HCV-related cirrhosis. DNA fragmentation was determined semi-quantitatively by in situ end labeling. HCV RNA and liver Fas mRNA were determined in parallel by quantitative polymerase chain reaction, with ribosomal 28S RNA as internal standard. RESULTS: Apoptotic lesions were predominantly portal (nonhepatocytic) or lobular (hepatocytic). Both were correlated with serum aminotransferase levels. The degree of portal apoptosis correlated with acute rejection (P<0.001), although lobular apoptosis was associated with lobular hepatitis (P<0.02), and HCV genotype 1b (P=0.04). In multivariate analysis, liver Fas mRNA level independently correlated with HCV-related chronic active hepatitis (P=0.04), age (P=0.01), and liver HCV RNA level (P=0.0007). CONCLUSIONS: After liver transplantation, 1) apoptosis is involved in HCV-related liver damage; 2) HCV type 1b may induce more severe apoptotic lesions than other genotypes; and 3) Fas transcription may be up-regulated by intrahepatic HCV replication.


Subject(s)
Hepacivirus/genetics , Hepatitis C/genetics , Hepatitis C/surgery , fas Receptor/pharmacology , Apoptosis/drug effects , DNA Fragmentation , Female , Follow-Up Studies , Genotype , Hepatitis C/pathology , Humans , Liver/pathology , Male , RNA, Viral/metabolism , Viral Load
20.
J Hepatol ; 33(1): 121-7, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10905595

ABSTRACT

BACKGROUND/AIMS: The prevalence and pathogenicity of TT virus, recently identified in patients with non A-non G post-transfusional hepatitis, are questioned. METHODS: We investigated the impact of this new viral infection in a large series of patients with non A-non G, cryptogenic, non-viral and viral-related, acute and chronic liver diseases (n=577) and blood donors (n=300). TTV DNA was detected in serum by hemi-nested polymerase chain reaction. Phylogenetic analysis was performed in 13 isolates. RESULTS: TTV DNA was detected in 6/25 and 15/127 patients with cryptogenic non A-non G acute and chronic liver disease, respectively. TTV DNA positive subjects with post-transfusional acute hepatitis scored negative before transfusion. TTV prevalence was increased in patients with cryptogenic non A-non G acute and chronic liver disease compared to blood donors (6/300; p<0.001) and non-viral-related chronic liver diseases (6/137; p<0.05). TTV/HBV coinfection was frequently identified (35/147), but this was not the case for HCV-infected subjects (4/77). Transaminase activity or liver histological score was not significantly increased among TTV positive, HBV infected or non A-non G patients. The HBV infection and Mediterranean origin were the risk factors associated with TTV infection. The majority of analysed sequences clustered in genotype 1 (8=1b; 3=1a). Two isolates showed homology to genotype 2. CONCLUSIONS: These results support the view that TTV is a widely spread infectious agent with a weak pathogenicity. It raises the possibility, however, that TTV might be implicated in a few cases of acute and chronic non A-non G hepatitis. TTV-DNA-analysed sequences are related to genotypes 1 and 2 described in Europe.


Subject(s)
DNA Virus Infections/complications , Liver Diseases/virology , Torque teno virus , Acute Disease , Blood Donors , Chronic Disease , DNA Virus Infections/epidemiology , DNA, Viral/analysis , France , Hepatitis B/complications , Hepatitis C/complications , Hepatitis, Viral, Human/virology , Humans , Italy , Liver Diseases/etiology , Prevalence , Retrospective Studies , Torque teno virus/genetics , Transfusion Reaction
SELECTION OF CITATIONS
SEARCH DETAIL
...